<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have developed a novel, non-toxic inhibitor of advanced glycation and <z:mp ids='MP_0003674'>oxidative stress</z:mp>, TM2002, devoid of effect on blood pressure </plain></SENT>
<SENT sid="1" pm="."><plain>In transient focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, TM2002 significantly decreased <z:mpath ids='MPATH_124'>infarct</z:mpath> volume compared with vehicle (79.5+/-18.7 vs. 183.3+/-22.9 mm3, p&lt;0.01) </plain></SENT>
<SENT sid="2" pm="."><plain>In permanent focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>, TM2002 (2.79, 5.58, and 11.16 mg/kg twice a day) dose-dependently reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (242.1+/-32.3, 201.3+/-15.1, and 171.3+/-15.2 mm3, respectively), and improved neurological deficits </plain></SENT>
<SENT sid="3" pm="."><plain>Reduction of <z:mpath ids='MPATH_124'>infarct</z:mpath> volume is demonstrable, provided that TM2002 was administered within 1.5 h after the occlusion </plain></SENT>
<SENT sid="4" pm="."><plain>To unravel TM2002's mechanism of action, we examined its in vitro effect on endoplasmic reticulum (ER) stress, using aortic smooth muscle cells isolated from ORP 150(+/-) mice and F9 Herp null mutated cells </plain></SENT>
<SENT sid="5" pm="."><plain>Cell <z:hpo ids='HP_0011420'>death</z:hpo> induced by ER stress (tunicamycin or <z:mp ids='MP_0005039'>hypoxia</z:mp>) was dose-dependently prevented by TM2002 </plain></SENT>
<SENT sid="6" pm="."><plain>In vivo immunohistochemical study demonstrated a significant reduction of ORP- and TUNEL-positive apoptotic cells, especially in the penumbra </plain></SENT>
<SENT sid="7" pm="."><plain>Inhibition of advanced glycation and <z:mp ids='MP_0003674'>oxidative stress</z:mp> was confirmed by a significantly reduced number of cells positive for advanced glycation end products and <z:chebi fb="4" ids="30413">heme</z:chebi> oxygenase-1 </plain></SENT>
<SENT sid="8" pm="."><plain>TM2002 reduced the levels of protein <z:chebi fb="1" ids="23019">carbonyl</z:chebi> formation in ischemic caudate </plain></SENT>
<SENT sid="9" pm="."><plain>The efficacy of TM2002 is equivalent to that of a known neuroprotective agent, NXY-059 </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, TM2002 significantly ameliorates ischemic cerebral damage through reduction of ER stress, advanced glycation, and <z:mp ids='MP_0003674'>oxidative stress</z:mp>, independently of blood pressure lowering </plain></SENT>
</text></document>